Chen Zhaolin, Hu Ying, Jin Le, Yang Fan, Ding Haiwen, Zhang Lei, Li Lili, Pan Tingting
Department of Pharmacy, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Anhui Provincial Hospital, Hefei, China.
Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, School of Pharmacy, Anhui Medical University, Hefei, China.
Front Pharmacol. 2022 Apr 6;13:873030. doi: 10.3389/fphar.2022.873030. eCollection 2022.
N6-methyladenosine (mA) RNA methylation has been considered the most prevalent, abundant, and conserved internal transcriptional modification throughout the eukaryotic mRNAs. Typically, mA RNA methylation is catalyzed by the RNA methyltransferases (writers), is removed by its demethylases (erasers), and interacts with mA-binding proteins (readers). Accumulating evidence shows that abnormal changes in the mA levels of these regulators are increasingly associated with human tumorigenesis and drug resistance. However, the molecular mechanisms underlying mA RNA methylation in tumor occurrence and development have not been comprehensively clarified. We reviewed the recent findings on biological regulation of mA RNA methylation and summarized its potential therapeutic strategies in various human cancers.
N6-甲基腺苷（m⁶A）RNA甲基化被认为是真核生物mRNA中最普遍、最丰富且最保守的内部转录修饰。通常，m⁶A RNA甲基化由RNA甲基转移酶（写入器）催化，由其去甲基化酶（擦除器）去除，并与m⁶A结合蛋白（读取器）相互作用。越来越多的证据表明，这些调节因子的m⁶A水平异常变化与人类肿瘤发生和耐药性越来越相关。然而，m⁶A RNA甲基化在肿瘤发生和发展中的分子机制尚未得到全面阐明。我们综述了m⁶A RNA甲基化生物学调控的最新研究结果，并总结了其在各种人类癌症中的潜在治疗策略。
